GI
ABUS icon

GAMMA Investing’s Arbutus Biopharma ABUS Stock Holding History

GAMMA Investing’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$870 Sell
182
-46
-20% -$222 ﹤0.01% 4124
2026
Q2 		$1.09K Buy
228
+46
+25% +$202 ﹤0.01% 3860
2026
Q1 		$819 Buy
+182
New +$796 ﹤0.01% 3878
2025
Q2 		– Sell
-127
Closed -$443 – 3771
2025
Q1 		$443 Sell
127
-60
-32% -$200 ﹤0.01% 3691
2024
Q4 		$611 Hold
187
– – ﹤0.01% 3537
2024
Q3 		$720 Hold
187
– – ﹤0.01% 3333
2024
Q2 		$578 Hold
187
– – ﹤0.01% 3184
2024
Q1 		$482 Hold
187
– – ﹤0.01% 3109
2023
Q4 		$443 Buy
+187
New +$366 ﹤0.01% 2987

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's ABUS Position: Q3 2026 in Review

GAMMA Investing reduced its Arbutus Biopharma (ABUS) stake by 20% in Q3 2026, selling an estimated $222 and leaving 182 shares worth $870. The position accounts for ﹤0.01% of the portfolio, ranked #4124.

GAMMA Investing first reported a position in ABUS in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.09K in Q2 2026. 5 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • GAMMA Investing held 182 shares of Arbutus Biopharma worth $870 as of Q3 2026.
  • GAMMA Investing sold 46 Arbutus Biopharma shares in Q3 2026, an estimated $222.
  • Arbutus Biopharma made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4124 holding.
  • GAMMA Investing first reported a position in Arbutus Biopharma in Q4 2023 and has held it in 9 quarters since.
  • GAMMA Investing's Arbutus Biopharma position peaked at $1.09K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.